Randomised trial to compare the clinical value of cyclosporin C12 and C2 monitoring after lung transplantation

Status

Active, not recruiting

Phases

Unknown

Study type

Interventional

Source

ISRCTN

Registry ID

ISRCTN17970029

Enrollment

Registered

2005-07-08

Start date

2003-04-01

Completion date

Unknown

Last updated

2018-07-30

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Lung transplant recipients Surgery Transplanted organ and tissue status

Interventions

Patients will be randomised into 3 groups to compare the clinical value of both 'high' and 'low' C2 monitoring strategies with conventional C12 monitoring as a guide to cyclosporin Neoral dosage adjus

Eligibility

Sex/Gender

All

Inclusion criteria

Inclusion criteria: 90 patients lung transplant: 1. Adult single or double lung and heart + lung transplant recipients (18 years and older) 2. Patients receiving Neoral as primary immunosuppression

Exclusion criteria

Exclusion criteria: 1. Patients not giving voluntary, written informed consent to participate 2. Re-transplantation 3. Simultaneous kidney, pancreas, liver or bowel transplantation 3. Urine output <50 ml/hour and/or serum creatinine =170 mmol/l at the most recent investigation prior to transplantation 4. Renal replacement therapy or any form of renal support such as continuous veno-venous haemofiltration (CVVH) or dialysis before transplantation or within the first post-operative week 5. Patients receiving tacrolimus or sirolimus as primary immuno-suppression in place of Neoral

Design outcomes

Primary

Measure	Time frame
Renal function at 3 months post transplant	—

Secondary

Measure	Time frame
Not provided at time of registration	—

Countries

United Kingdom

Outcome results

None listed

Source: ISRCTN (via WHO ICTRP) · Data processed: Feb 4, 2026